Orestes de Jesús Cobos-Quevedo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Orestes de Jesús Cobos-Quevedo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Abihai Lucas-Hernández
Departamento de estudios de Posgrado, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico
1 shared publication - Alberto Avendaño-Ponce
Department of Internal Medicine, Hospital de Especialidades Dr. Antonio Fraga Mouret Centro Medico Nacional “La Raza”, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico
1 shared publication - Ana Lilia Peralta-Amaro
Division of Postgraduate Studies, Universidad Nacional Autónoma de México, Mexico City, Mexico; Internal Medicine Department, Hospital de Especialidades Dr. Antonio Fraga Mouret, Centro Médico Nacional "La Raza", Instituto Mexicano del Seguro Social, Mexico City, Mexico
1 shared publication - Jorge Hurtado-Díaz
Division of Post-graduate Studies, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City 04360, Mexico
1 shared publication - Karen Lilian Rivera-Alvarado
Division of Post-graduate Studies, Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City 04360, Mexico
1 shared publication - Melina Ivone Tejada-Ruiz
Department of Internal Medicine, Hospital de Especialidades Dr. Antonio Fraga Mouret Centro Medico Nacional “La Raza”, Instituto Mexicano del Seguro Social, Mexico City 02990, Mexico
1 shared publication
Latest Publications
- Open Access
Atypical Kawasaki Disease after COVID-19 Vaccination: A New Form of Adverse Event Following Immunization
Kawasaki disease (KD) is a medium-vessel vasculitis that is typically presented during childhood; fewer than 100 cases of KD have been reported worldwide in adult patients who met the criteria according to the American College of Rheumatology. This study presents the case of an 18-year-old patient with no previous history of any disease, who presented atypical KD with liver and kidney dysfunction, with a good response to intravenous immunoglobulin therapy. The symptoms began 22 days after the application of the COVID-19 vaccine (nonreplicating viral vector Vaxzevria), and other conditions were ruled out. The term Adverse Events Following Immunization (AEFI)encompasses all the reactions that follow the application of any vaccine with no necessary causal relationship and can be due to the vaccine product, quality of the vaccine, immunization errors, or anxiety or just happen to be coincident events. These reactions should be reported so that clinicians can identify compatible cases and consider that the presentation of this disease, despite being atypical, can be manifested in adult patients. Likewise, case reports are an important basis for the pharmacovigilance of vaccines.
Open AccessAtypical Kawasaki Disease after COVID-19 Vaccination: A New Form of Adverse Event Following Immunization
Kawasaki disease (KD) is a medium-vessel vasculitis that is typically presented during childhood; fewer than 100 cases of KD have been reported worldwide in adult patients who met the criteria according to the American College of Rheumatology. This study presents the case of an 18-year-old patient with no previous history of any disease, who presented atypical KD with liver and kidney dysfunction, with a good response to intravenous immunoglobulin therapy. The symptoms began 22 days after the application of the COVID-19 vaccine (nonreplicating viral vector Vaxzevria), and other conditions were ruled out. The term Adverse Events Following Immunization (AEFI)encompasses all the reactions that follow the application of any vaccine with no necessary causal relationship and can be due to the vaccine product, quality of the vaccine, immunization errors, or anxiety or just happen to be coincident events. These reactions should be reported so that clinicians can identify compatible cases and consider that the presentation of this disease, despite being atypical, can be manifested in adult patients. Likewise, case reports are an important basis for the pharmacovigilance of vaccines.